Table 1.

Ethnicity and MED12 Mutation Status of Patient Samples

Sample	Race/Ethnicity	MED12 status	HMGA2 OE
LSC, LIC, and LDC MethylCap-Seq PT1	African American	MED12 G44S	No
LSC, LIC, and LDC MethylCap-Seq PT2	African American	MED12 G44S	No
LSC, LIC, and LDC MethylCap-Seq PT3	African American	WT	No
LSC, LIC, and LDC RNA-Seq PT1	Caucasian	WT	No
LSC, LIC, and LDC RNA-Seq PT2	Declined to answer	WT	No
LSC, LIC, and LDC RNA-Seq PT3	African American	WT	No
LSC, LIC, and LDC RNA-Seq PT4	African American	G44V	No
5’-Aza or Veh-treated LM RNA-Seq PT1	Caucasian	WT (after culture)	No
5’-Aza or Veh-treated LM RNA-Seq PT2	Caucasian	WT (after culture)	No
5’-Aza or Veh-treated LM RNA-Seq PT3	African American	WT (after culture)	No

Abbreviations: G44S, glycine to Serine mutation; HMGA2, high Mobility Group AT-Hook 2; LDC, leiomyoma differentiated cells; LIC, leiomyoma intermediated cells; LSC, leiomyoma stem cells; LM, Leiomyomas; MED12, Mediator complex subunit 12; OE, Overexpression; PT, patient; WT, wildtype.